The radiotherapy systems include TrueBeam, TrueBeam STx, VitalBeam, and Edge
These approvals represent a defining moment for people living with classical Hodgkin Lymphoma
The trial met its primary endpoint, with the combination therapy demonstrating a “statistically significant and clinically meaningful” improvement in radiographic progression-free survival
The study hit its primary endpoint, demonstrating a statistically significant and clinically meaningful improvement in radiographic progression-free survival (rPFS) compared to placebo plus XTANDI
The drug also showed a manageable safety profile, with just 6.4% of patients stopping treatment due to side effects. No new safety concerns emerged
The partnership will focus on advancing fault-tolerant quantum algorithms and developing clinically relevant quantum applications
AstraZeneca says the approval strengthens its push to bring immunotherapy earlier into cancer treatment, where long-term cures are possible
The trial enrolled patients with stage IV pancreatic cancer, where median life expectancy is just 6 to 12 months
The new entity will operate with separate resources, funding, and operations, while BioNTech will contribute related rights and mRNA technologies to support its ambitious mission
Subscribe To Our Newsletter & Stay Updated